1027253-76-4

Basic information

• Product Name: N-(3-{(1S)-1-[(6-bromopyridin-2-yl)amino]ethyl}phenyl)-5-methylnicotinamide
• Synonyms: N-(3-{(1S)-1-[(6-bromopyridin-2-yl)amino]ethyl}phenyl)-5-methylnicotinamide
• CAS NO: 1027253-76-4
• Molecular Weight: 411.301
• Mol File: 1027253-76-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-(3-{(1S)-1-[(6-bromopyridin-2-yl)amino]ethyl}phenyl)-5-methylnicotinamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-{(1S)-1-[(6-bromopyridin-2-yl)amino]ethyl}phenyl)-5-methylnicotinamide(1027253-76-4)
• EPA Substance Registry System: N-(3-{(1S)-1-[(6-bromopyridin-2-yl)amino]ethyl}phenyl)-5-methylnicotinamide(1027253-76-4)

Safety Data

• Hazardous Substances Data: 1027253-76-4(Hazardous Substances Data)

Upstream product

• 3222-49-9 5-methylnicotinic acid 
• 1027256-71-8 N-[(1S)-1-(3-aminophenyl)ethyl]-6-bromopyridin-2-amine 

Relevant articles and documents

INHIBITORS OF KINASE ACTIVITY

The present invention relates to pyridines or pyrazines that inhibit kinases. In particular the compounds of the invention inhibit members of the class III PTK receptor family such as FMS (CSF-IR), c-KIT, PDGFRβ, PDGFRα or FLT3 and KDR, SRC, EphA2, EphA3, EphA8, FLTl, FLT4, HCK, LCK, PTK5 (FRK), SYK, DDRl and DDR2 and RET. The compounds of the invention are useful in the treatment of kinase associated diseases such as immunological and inflammatory diseases; hyperproliferative diseases including cancer and diseases involving neo-angiogenesis; renal and kidney diseases; bone remodeling diseases; metabolic diseases; and vascular diseases.